NCT03494881 - Mepolizumab for the Treatment of Chronic Spontaneous Urticaria | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 30, 2019

Primary Completion Date

November 15, 2023

Study Completion Date

February 25, 2025

Conditions

Chronic Spontaneous Urticaria

Interventions

DRUG

Nucala

All study participants will receive Nucala (2) 100mg SQ injections administered at two different anatomical sites at week zero, 2,4,6, and 8 for a total of 5 doses.

Trial Locations (1)

32224

Mayo Clinic in Florida, Jacksonville